Ubs Group Ag Argenx Se Transaction History
Ubs Group Ag
- $527 Billion
- Q4 2024
A detailed history of Ubs Group Ag transactions in Argenx Se stock. As of the latest transaction made, Ubs Group Ag holds 19,900 shares of ARGX stock, worth $12.7 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
19,900
Previous 1,917
938.08%
Holding current value
$12.7 Million
Previous $1.04 Million
1077.86%
% of portfolio
0.0%
Previous 0.0%
Shares
29 transactions
Others Institutions Holding ARGX
# of Institutions
431Shares Held
29.2MCall Options Held
390KPut Options Held
272K-
Price T Rowe Associates Inc Baltimore, MD5.52MShares$3.53 Billion0.39% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI3.07MShares$1.96 Billion3.02% of portfolio
-
Janus Henderson Group PLC London, X02.31MShares$1.48 Billion0.76% of portfolio
-
Capital World Investors Los Angeles, CA1.79MShares$1.14 Billion0.17% of portfolio
-
Avoro Capital Advisors LLC New York, NY1.24MShares$791 Million11.1% of portfolio
About ARGENX SE
- Ticker ARGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,323,800
- Market Cap $35.4B
- Description
- argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...